(Q43921050)

28 November 2017

title

Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma (English)

1 reference

28 November 2017

1 reference

1 reference

Tom Pickles

1

1 reference

28 November 2017

Alex Agranovich

2

1 reference

28 November 2017

Eric Berthelet

3

1 reference

28 November 2017

Graeme G Duncan

4

1 reference

28 November 2017

Mira Keyes

5

1 reference

28 November 2017

Winkle Kwan

6

1 reference

28 November 2017

Michael R McKenzie

7

1 reference

28 November 2017

W James Morris

8

1 reference

28 November 2017

British Columbia Cancer Agency, Prostate Cohort Outcomes Initiative

9

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

94

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

362-367

1 reference

Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Leydig cell function and radiation: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Influence of radical prostatectomy on serum hormone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Clinical pharmacokinetics of goserelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Response to orchiectomy following zoladentherapy for metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Testicular Endocrine Function after Withdrawal of Oestrogen Treatment in Patients with Carcinoma of the Prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Low-dose cyproterone acetate plus mini-dose diethylstilbestrol—A protocol for reversible medical castration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Effects of androgen treatment in impotent men with normal and low levels of free testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10219

21 January 2018

Identifiers

DOI

10.1002/CNCR.10219

1 reference

28 November 2017

1 reference